Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mg Oxide | Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks |
| |
| placebo | placebo 1 tab TDS |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mg Oxide | Drug | 250 mg orally for 4 weeks |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| plasma phosphate level | 4 week |
Not provided
Not provided
Inclusion Criteria:
hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.
Exclusion Criteria:
Mg level >3 mg/dl
Not provided
Not provided
hemodialysis patients
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shiraz University Hemodialysis Center | Shiraz | Fars | o98-711 | Iran |
Not provided
| ID | Term |
|---|---|
| D054559 | Hyperphosphatemia |
| ID | Term |
|---|---|
| D010760 | Phosphorus Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided